UPDATED: Living in its post-Shire world, Takeda continues aggressive licensing push in $2.3B deal with Anima
As Takeda continues charting its post-Shire merger course, the Japanese drugmaker has offloaded expensive chunks of the combined business while taking an aggressive stance on licensing deals to place bets on the future. On Thursday, they made another one of those bets potentially to the tune of several billion dollars.
Takeda has signed a collaboration with Israeli firm Anima Biotech, covering up to six different programs with promises of up to $2.3 billion in milestones. Under the deal, Anima will initially conduct preclinical research for Huntington’s disease, as well as two other small molecule candidates.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.